BioSpace News Archive

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) today presented further analyses of the Phase 1 INTERCEPT-AD trial evaluating ACU193, the first clinical-stage AβO-targeting antibody, at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston and online.

Boys with Duchenne muscular dystrophy (DMD) have a clinically proven, new treatment option with the Food and Drug Administration’s approval Thursday of vamorolone, a steroidal-type, anti-inflammatory drug developed based on research performed at Children’s National Hospital.

Sirtex Medical (“Sirtex”), a leading manufacturer of interventional treatment solutions, announced today the commercial availability of the LAVA® Liquid Embolic System, the first and only liquid embolic approved for the treatment of peripheral vascular hemorrhage.

Global biotechnology leader CSL and uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced that the companies have received the 2023 Prix Galien USA Award in the category of Best Product for Rare/Orphan Diseases for HEMGENIX®.

L2P Research, LLC, a leading preclinical CRO, today announced the award of a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH).

In an era marked by relentless change and the pressing need to adapt, Psychemedics, a pioneer in the drug screening industry, proudly announces the launch of a revolutionary, Advanced 5-Panel Drug Screen.

Oncoinvent AS today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for the phase 2b study for Radspherin® in patients with peritoneal carcinomatosis from colorectal cancer.

Bruker Corporation (Nasdaq: BRKR) today announced it will report third quarter 2023 financial results before market opening on Thursday, November 2, 2023.

Somerset Pharma, LLC, a leading US-based pharmaceutical company specializing in sterile injectables and ophthalmic products, announces the introduction of Calcium Gluconate 100mg/mL in two sizes, 50mL and 100mL.

PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLD) (“PharmaDrug” or the “Company”), is pleased to announce that it has entered into a definitive agreement (the “Acquisition Agreement”) dated October 27, 2023 pursuant to which PharmaDrug will acquire all of the issued and outstanding shares of privately-held Securedose Synthetics Inc.